← Eichor
Study identifier: NCT06069570 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Condition: Carcinoma, Non-Small-Cell Lung Cancer · Bone Metastases From Solid Tumors  ·  Sponsor: Kiromic BioPharma Inc.

PhasePhase 1
Planned participants48
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Matthew Wagener, BS  ·  1-844-539-2873  ·  mwagener@kiromic.com

Leonardo Mirandola, PhD  ·  1-844-539-2873  ·  lmirandola@kiromic.com

Always discuss trial participation with your own doctor first.

Locations (5)

The University of Arizona Cancer CenterTucson, Arizona, United StatesNot Yet Recruiting
Beverly Hills Cancer CenterBeverly Hills, California, United StatesRecruiting
UPMC Hillman Cancer CenterPittsburgh, Pennsylvania, United StatesRecruiting
Texas Oncology - TylerTyler, Texas, United StatesRecruiting
Virginia Oncology AssociatesNorfolk, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06069570